Consequently, mice with a myeloid specific deletion of Camkk2 are protected from high fat diet-induced obesity, insulin resistance and hepatosteatosis, highlighting CAMKK2 as an attractive therapeutic target for the treatment of inflammatory and metabolic diseases. This evidence concerns the gene CAMKK2 and Other metabolic disease.